Loading clinical trials...
Loading clinical trials...
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of non-gene edited anti-CD7 CAR (also called anti-CD7 CAR) T cells in patients with r...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
iCell Gene Therapeutics
Collaborators
NCT04972942 · T-cell Acute Lymphoblastic Leukemia, T-Cell Acute Lymphoblastic Lymphoma
NCT07523555 · Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, and more
NCT05376111 · T-cell Acute Lymphoblastic Leukemia, Recruiting
NCT05679895 · T-cell Acute Lymphoblastic Leukemia, Lymphoblastic T-Cell Lymphoma
NCT07356245 · T-cell Lymphoma, Graft Versus Host Disease, and more
Peking University Shenzhen Hospital
Shenzhen, Guangdong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions